ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Verve Therapeutics Inc

Verve Therapeutics Inc (VERV)

8.16
-0.20
(-2.39%)
Closed February 09 3:00PM
8.16
0.00
(0.00%)
After Hours: 6:01PM

Calls

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.504.606.605.455.600.000.00 %0319-
5.002.354.103.403.2250.000.00 %0138-
7.501.001.201.051.10-0.35-25.00 %161,7942/06/2025
10.000.050.150.200.100.000.00 %0777-

Empower your portfolio: Real-time discussions and actionable trading ideas.

Puts

StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
2.500.130.050.130.090.000.00 %070-
5.000.030.200.030.1150.000.00 %01,084-
7.500.150.300.700.2250.000.00 %0147-
10.001.452.852.302.150.000.00 %0255-

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
780.46M
CDTConduit Pharmaceuticals Inc
US$ 2.831
(82.65%)
140.32M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
215.16M
TOIIWOncology Institute Inc
US$ 0.033
(58.88%)
7.27k
CYTHCyclo Therapeutics Inc
US$ 1.19
(54.55%)
72.39M
FTELFitell Corporation
US$ 2.70
(-57.01%)
2.3M
SGBXSafe and Green Holdings Corporation
US$ 0.6401
(-44.82%)
5.65M
NKLANikola Corporation
US$ 0.4432
(-41.10%)
52.44M
PLRXPliant Therapeutics Inc
US$ 7.785
(-34.85%)
6.44M
LIPOLipella Pharmaceuticals Inc
US$ 3.08
(-33.76%)
2.2M
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
816.59M
RIMEAlgorhythm Holdings Inc
US$ 0.0169
(-20.66%)
274.2M
NVDANVIDIA Corporation
US$ 129.84
(0.90%)
228.2M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
219.64M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0537
(14.74%)
212.29M

VERV Discussion

View Posts
Monksdream Monksdream 6 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 6 months ago
VERV 10Q due AUGUST5
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
VERV more new lows up ahead
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
VERV new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
VERV new 52 lo
πŸ‘οΈ0
Firestorm22 Firestorm22 10 months ago
uh oh
πŸ‘οΈ0
Monksdream Monksdream 10 months ago
VERV over $10
πŸ‘οΈ0
fink fink 12 months ago
Looking for an entry now
πŸ‘οΈ0
Terpi Terpi 1 year ago
Could see another nice move here is the 50 day holds into close.
πŸ‘οΈ0
Monksdream Monksdream 1 year ago
VERV morning rally
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
https://cathiesark.com/
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
VERV IS A GREAT $$$$$ OPPORTUNITY.
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
πŸ‘οΈ0
crudeoil24 crudeoil24 3 years ago
Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
πŸ‘οΈ0